In lupus-prone MRL/lpr mice, intraperitoneal administration of 3-deazaneplanocin A (DZNep), an EZH2 inhibitor, improved survival and significantly reduced anti-dsDNA antibody levels. This evidence concerns the gene EZH2 and systemic lupus erythematosus.